SCHOTT Pharma AG & Co. KGaA Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
1SXP Community Narratives
Advanced Drug Delivery And Capacity Investments Will Shape Future Success
Intensifying Climate Mandates And Protectionism Will Erode Prospects
Aging Population And Biologics Growth Will Fuel Advanced Packaging
Intensifying Climate Mandates And Protectionism Will Erode Prospects
View narrativeAging Population And Biologics Growth Will Fuel Advanced Packaging
View narrativeAdvanced Drug Delivery And Capacity Investments Will Shape Future Success
View narrativeTrending Discussion
No trending discussion available.
Recently Updated Narratives
1SXP: Higher Future P/E And Rich Margins Will Limit Share Return Potential
1SXP: Expanded U.S. Vial Capacity Will Support Future Upside For Undervalued Shares
1SXP: Lebanon Expansion And Confirmed 2026 Guidance Will Support Balanced Outlook
Snowflake Analysis
SCHOTT Pharma AG & Co. KGaA Key Details
- 0.90
- 31.17%
- 13.40%
- 23.2%
About 1SXP
- Founded
- 1884
- Employees
- 5002
- CEO
- Website
View website
SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT TOPPAC sensitive, a polymer syringe for sensitive drugs; SCHOTT TOPPAC infuse, a polymer syringe for infusion therapy; SCHOTT TOPPAC unique, a polymer container; and SCHOTT TOPPAC cartridge. It also provides pharmaceutical glass cartridge, such as cartriQ for peptide and protein-based injectables; cartriQ Large Volume for large-volume injectables; Cartridges Double Chamber for lyophilized drugs; Cartridges Break Resistant; and TopLine and StandardLine cartridges and vials. In addition, the company offers pharmaceutical glass vial, including adaptiQ for injectables; EVERIC pure for unmatched drug stability; EVERIC freeze for deep-cold applications; EVERIC care for a pH range; EVERIC strong & smooth for the filling line performance; EVERIC smart; EVERIC plus for sensitive drug formulations; and EVERIC Iyo to avoid fogging for lyophilized drugs. Further, it provides pharmaceutical glass ampoule products, comprising Ampoules easyOPC for ampoule opening; Ampoules Anti-Counterfeiting for protection against drug counterfeiting; and StandardLine ampoules. It also provides containment and drug delivery, analytics, fill-and-finish, regulatory, and sustainability services. The company was founded in 1884 and is headquartered in Mainz, Germany. SCHOTT Pharma AG & Co. KGaA operates as a subsidiary of Schott Glaswerke Beteiligungs- Und Export Gmbh.